BIO Bio Rad Laboratories Inc

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024.

Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterly sales increased 3.4 percent compared to the same period in 2023. The increase in net sales was driven by higher sales in our Clinical Diagnostics segment.

Life Science segment net sales for the third quarter were $260.9 million, a decrease of 1.0 percent compared to the same period in 2023. On a currency-neutral basis, sales decreased by 0.6 percent compared to the same quarter in 2023, driven by ongoing weakness in the biotech and biopharma end markets. Currency neutral sales decreased in the Americas, offset by increases in EMEA.

Clinical Diagnostics segment net sales for the third quarter were $388.8 million, an increase of 5.6 percent compared to the same period in 2023. On a currency-neutral basis, sales increased 6.4 percent compared to the same quarter last year. The currency neutral sales increase was primarily driven by increased demand for quality control products, and a favorable compare for our immunology products, which were impacted by supply constraints in the third quarter of 2023. Currency neutral sales increased across all regions.

Third-quarter gross margin was 54.8 percent compared to 53.1 percent during the third quarter of 2023.

Income from operations during the third quarter of 2024 was $64.5 million versus $90.9 million during the same quarter last year.

During the third quarter of 2024, the company recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a net income of $653.2 million, or $23.34 per share, on a diluted basis, versus a net income of $106.3 million, or $3.64 per share, on a diluted basis, reported for the same period of 2023.

The effective tax rate for the third quarter of 2024 was 24.2 percent, compared to 22.5 percent for the same period in 2023. The effective tax rate reported in these periods was primarily affected by the accounting treatment of our equity securities.

“Our third-quarter revenue performance was slightly ahead of expectations, driven by steady growth in clinical diagnostics products, while our life science business continued to improve reflecting a gradual recovery in the biopharma end market,” said Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer. "During the quarter, we also welcomed Jon DiVincenzo as President and Chief Operating Officer. Jon joins Bio-Rad's other recently hired senior executives who collectively bring a wealth of life science, clinical diagnostics, and operations experience. With the new senior leadership team in place, we are focused on margin expansion, commercial excellence, and creating long-term shareholder value."

The non-GAAP financial measures discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP and Currency-Neutral Reporting.” A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Non-GAAP gross margin was 55.6 percent for the third quarter of 2024 compared to 53.9 percent during the third quarter of 2023.

Non-GAAP income from operations during the third quarter of 2024 was $73.3 million versus $81.6 million during the comparable prior-year period.

Non-GAAP net income for the third quarter of 2024 was $56.4 million, or $2.01 per share, on a diluted basis, compared to $68.1 million, or $2.33 per share, on a diluted basis, during the same period in 2023.

The non-GAAP effective tax rate for the third quarter of 2024 was 28.8 percent, compared to 23.9 percent for the same period in 2023. The higher rate in 2024 was driven by geographical mix of earnings and a one-time acquired in-process research and development expense.

GAAP Results

 

Q3 2024

Q3 2023

Revenue (millions)

$

649.7

 

$

632.1

 

Gross margin

 

54.8

%

 

53.1

%

Operating margin

 

9.9

%

 

14.4

%

Net income (millions)

$

653.2

 

$

106.3

 

Income per diluted share

$

23.34

 

$

3.64

 

 

Non-GAAP Results

 

Q3 2024

Q3 2023

Revenue (millions)

$

649.7

 

$

632.1

 

Gross margin

 

55.6

%

 

53.9

%

Operating margin

 

11.3

%

 

12.9

%

Net income (millions)

$

56.4

 

$

68.1

 

Income per diluted share

$

2.01

 

$

2.33

 

Updated Full-Year 2024 Financial Outlook

Bio-Rad continues to expect its non-GAAP revenue to decline by approximately 2.5 to 4.0 percent on a currency-neutral basis. The company estimates a non-GAAP operating margin of between 12.75 to 13.25 percent, which now also includes the impact of a one-time acquired in-process research and development expense related to an acquisition completed during the third quarter.

Conference Call and Webcast

Management will discuss the company’s third quarter 2024 results and financial outlook in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) on October 30, 2024. To participate, dial 800-579-2543 within the U.S., or (+1) 785-424-1789 from outside the U.S., and provide access code: BIORAD.

A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.

Use of Non-GAAP and Currency-Neutral Reporting

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP EPS, which exclude amortization of acquisition-related intangible assets, certain acquisition-related expenses and benefits, restructuring charges, asset impairment charges, gains and losses from change in fair market value of equity securities and loan receivable, gains and losses on equity-method investments, and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies. More specifically, management adjusts for the excluded items for the following reasons:

Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.

Acquisition-related expenses and benefits: we incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, professional fees for assistance with the transaction; valuation or integration costs; changes in the fair value of contingent consideration, gain or loss on settlement of pre-existing relationships with the acquired entity; or adjustments to purchase price. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business.

Restructuring, impairment charges, and gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses on equity-method investments: we incur restructuring and impairment charges on individual or groups of employed assets and charges and benefits arising from gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses (including impairments) on equity-method investments, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.

Significant litigation charges or benefits and legal costs: we may incur charges or benefits as well as legal costs in connection with litigation and other contingencies unrelated to our core operations. We exclude these charges or benefits, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of on-going business and operating results.

Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.

From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.

Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales.

There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results. The presentation of this additional information is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP in the United States. Investors should review the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments or future legal charges or benefits), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all.

BIO-RAD is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.

Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results; being focused on margin expansion, commercial excellence, and creating long-term shareholder value; and for the full-year 2024: continuing to expect non-GAAP revenue to decline by approximately 2.5 to 4.0 percent on a currency-neutral basis and estimating a non-GAAP operating margin of between 12.75 to 13.25 percent. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "expect,” "estimate," "continue," "believe," "anticipate," “target,” "will," "project," "assume," "may," "intend," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include reductions in government funding or capital spending of our customers, global economic and geopolitical conditions, the uncertain pace of the biopharma sector’s recovery, the challenging macroeconomic environment in China, supply chain issues, international legal and regulatory risks, our ability to develop and market new or improved products, our ability to compete effectively, foreign currency exchange fluctuations, product quality and liability issues, our ability to integrate acquired companies, products or technologies into our company successfully, changes in the healthcare industry, and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.

Bio-Rad Laboratories, Inc.

Condensed Consolidated Statements of Income (Loss)

(In thousands, except per share data)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30,

 

September 30,

 

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

Net sales

$

649,729

 

$

632,124

 

$

1,899,025

 

$

1,990,078

 

Cost of goods sold

 

293,826

 

 

296,441

 

 

862,037

 

 

929,495

 

Gross profit

 

355,903

 

 

335,683

 

 

1,036,988

 

 

1,060,583

 

Selling, general and administrative expense

 

200,440

 

 

201,199

 

 

610,042

 

 

634,576

 

Research and development expense

 

90,997

 

 

43,535

 

 

216,276

 

 

183,528

 

Income from operations

 

64,466

 

 

90,949

 

 

210,670

 

 

242,479

 

Interest expense

 

12,174

 

 

12,398

 

 

36,715

 

 

37,078

 

Foreign currency exchange (gains) losses, net

 

1,641

 

 

(1,680

)

 

(2,012

)

 

(5,280

)

(Gains) losses from change in fair market value of equity securities and loan receivable

 

(792,888

)

 

(36,425

)

 

1,680,290

 

 

1,576,542

 

Other income, net

 

(18,081

)

 

(20,446

)

 

(70,740

)

 

(87,365

)

Income (loss) before income taxes

 

861,620

 

 

137,102

 

 

(1,433,583

)

 

(1,278,496

)

(Provision for) benefit from income taxes

 

(208,448

)

 

(30,845

)

 

305,185

 

 

291,464

 

Net income (loss)

$

653,172

 

$

106,257

 

$

(1,128,398

)

$

(987,032

)

  Basic earnings (loss) per share: Net income (loss) per basic share

$

23.37

 

$

3.65

 

$

(39.89

)

$

(33.63

)

Weighted average common shares - basic

 

27,949

 

 

29,102

 

 

28,286

 

 

29,349

 

  Diluted earnings (loss) per share: Net income (loss) per diluted share

$

23.34

 

$

3.64

 

$

(39.89

)

$

(33.63

)

Weighted average common shares - diluted

 

27,985

 

 

29,223

 

 

28,286

 

 

29,349

  Note:   As a result of the net loss for the nine months ended September 30, 2024 and 2023,     all potentially issuable common shares have been excluded from the diluted shares     used in the computation of earnings per share as their effect was anti-dilutive.

Bio-Rad Laboratories, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

 

 

 

 

 

September 30,

 

December 31,

 

2024

 

2023

 

(Unaudited)

 

 

Current assets: Cash and cash equivalents

$

410,377

$

403,815

Short-term investments

 

1,217,641

 

1,208,887

Accounts receivable, net

 

461,940

 

489,017

Inventories, net

 

804,276

 

780,517

Other current assets

 

161,386

 

166,094

Total current assets

 

3,055,620

 

3,048,330

  Property, plant and equipment, net

 

545,304

 

529,007

Operating lease right-of-use assets

 

173,866

 

194,730

Goodwill, net

 

415,100

 

413,569

Purchased intangibles, net

 

307,325

 

320,514

Other investments

 

6,002,635

 

7,698,070

Other assets

 

103,622

 

94,850

Total assets

$

10,603,472

$

12,299,070

  Current liabilities: Accounts payable, accrued payroll and employee benefits

$

268,209

$

284,554

Current maturities of long-term debt

 

1,262

 

486

Income and other taxes payable

 

43,625

 

35,759

Other current liabilities

 

184,847

 

202,000

Total current liabilities

 

497,943

 

522,799

  Long-term debt, net of current maturities

 

1,200,062

 

1,199,052

Other long-term liabilities

 

1,417,608

 

1,836,086

Total liabilities

 

3,115,613

 

3,557,937

  Total stockholders' equity

 

7,487,859

 

8,741,133

Total liabilities and stockholders' equity

$

10,603,472

$

12,299,070

Bio-Rad Laboratories, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

 

 

 

 

 

Nine Months Ended

 

September 30,

 

 

2024

 

 

 

2023

 

  Cash flows from operating activities: Cash received from customers

$

1,920,985

 

$

2,007,482

 

Cash paid to suppliers and employees

 

(1,531,330

)

 

(1,722,173

)

Interest paid, net

 

(45,628

)

 

(46,394

)

Income tax payments, net

 

(75,710

)

 

(40,966

)

Other operating activities

 

62,731

 

 

95,947

 

Net cash provided by operating activities

 

331,048

 

 

293,896

 

  Cash flows from investing activities: Payments for purchases of marketable securities and investments

 

(1,053,660

)

 

(537,540

)

Proceeds from sales and maturities of marketable securities and investments

 

1,069,951

 

 

599,882

 

Other investing activities

 

(145,947

)

 

(114,331

)

Net cash used in investing activities

 

(129,656

)

 

(51,989

)

  Cash flows from financing activities: Payments on long-term debt

 

(359

)

 

(349

)

Other financing activities

 

(192,193

)

 

(224,678

)

Net cash used in financing activities

 

(192,552

)

 

(225,027

)

  Effect of foreign exchange rate changes on cash

 

(1,021

)

 

6,891

 

  Net increase in cash, cash equivalents and restricted cash

 

7,819

 

 

23,771

 

Cash, cash equivalents and restricted cash at beginning of period

 

404,369

 

 

434,544

 

Cash, cash equivalents and restricted cash at end of period

$

412,188

 

$

458,315

 

    Reconciliation of net loss to net cash provided by operating activities: Net loss

$

(1,128,398

)

$

(987,032

)

Adjustments to reconcile net loss to net cash provided by operating activities: Depreciation and amortization

 

112,393

 

 

108,724

 

Reduction in the carrying amount of right-of-use assets

 

31,066

 

 

30,725

 

Losses from change in fair market value of equity securities and loan receivable

 

1,680,290

 

 

1,576,542

 

Changes in working capital

 

(29,950

)

 

(61,623

)

Other

 

(334,353

)

 

(373,440

)

Net cash provided by operating activities

$

331,048

 

$

293,896

 

Bio-Rad Laboratories, Inc. Reconciliation of GAAP financial measures to non-GAAP financial measures (In thousands, except per share data) (Unaudited)

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use certain non-GAAP financial measures, including non-GAAP net income and non-GAAP diluted income per share (non-GAAP EPS), which exclude amortization of acquisition-related intangible assets; certain acquisition-related expenses and benefits; restructuring charges; asset impairment charges; gains and losses from change in fair market value of equity securities and loan receivable; gains and losses on equity-method investments; and significant legal-related charges or benefits and associated legal costs. Non-GAAP net income and non-GAAP EPS also exclude certain other gains and losses that are either isolated or cannot be expected to occur again with any predictability, tax provisions/benefits related to the previous items, and significant discrete tax events. We exclude the above items because they are outside of our normal operations and/or, in certain cases, are difficult to forecast accurately for future periods.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, forecasting and planning for future periods, and determining payments under compensation programs. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business. We believe that disclosing non-GAAP financial measures provides useful supplemental data that, while not a substitute for financial measures prepared in accordance with GAAP, allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies.

Three Months Ended Three Months Ended Nine Months Ended Nine Months Ended September 30, % of September 30, % of September 30, % of September 30, % of

 

2024

 

revenue

 

2023

 

revenue

 

2024

 

revenue

 

2023

 

revenue   GAAP cost of goods sold

$

293,826

 

$

296,441

 

$

862,037

 

$

929,495

 

Amortization of purchased intangibles

 

(4,499

)

 

(4,507

)

 

(13,391

)

 

(13,131

)

Restructuring benefits (costs)

 

(603

)

 

(215

)

 

(1,764

)

 

(3,922

)

Non-GAAP cost of goods sold

$

288,724

 

$

291,719

 

$

846,882

 

$

912,442

 

  GAAP gross profit

$

355,903

 

54.8

%

$

335,683

 

53.1

%

$

1,036,988

 

54.6

%

$

1,060,583

 

53.3

%

Amortization of purchased intangibles

 

4,499

 

 

4,507

 

 

13,391

 

 

13,131

 

Restructuring (benefits) costs

 

603

 

 

215

 

 

1,764

 

 

3,922

 

Non-GAAP gross profit

$

361,005

 

55.6

%

$

340,405

 

53.9

%

$

1,052,143

 

55.4

%

$

1,077,636

 

54.2

%

  GAAP selling, general and administrative expense

$

200,440

 

$

201,199

 

$

610,042

 

$

634,576

 

Amortization of purchased intangibles

 

(825

)

 

(1,629

)

 

(2,686

)

 

(4,931

)

Acquisition related benefits (costs)

 

-

 

 

4,100

 

 

-

 

 

4,100

 

Restructuring benefits (costs)

 

(819

)

 

(1,339

)

 

(3,825

)

 

(16,655

)

Other non-recurring items (2)

 

(1,663

)

 

(1,877

)

 

(4,704

)

 

(5,794

)

Non-GAAP selling, general and administrative expense

$

197,133

 

$

200,454

 

$

598,827

 

$

611,296

 

  GAAP research and development expense

$

90,997

 

$

43,535

 

$

216,276

 

$

183,528

 

Acquisition related benefits (costs)

 

(400

)

 

14,800

 

 

(800

)

 

14,400

 

Restructuring benefits (costs)

 

(19

)

 

22

 

 

(1,519

)

 

(5,293

)

Non-GAAP research and development expense

$

90,578

 

$

58,357

 

$

213,957

 

$

192,635

 

  GAAP income from operations

$

64,466

 

9.9

%

$

90,949

 

14.4

%

$

210,670

 

11.1

%

$

242,479

 

12.2

%

Amortization of purchased intangibles

 

5,324

 

 

6,136

 

 

16,077

 

 

18,062

 

Acquisition related (benefits) costs

 

400

 

 

(18,900

)

 

800

 

 

(18,500

)

Restructuring (benefits) costs

 

1,441

 

 

1,532

 

 

7,108

 

 

25,870

 

Other non-recurring items (2)

 

1,663

 

 

1,877

 

 

4,704

 

 

5,794

 

Non-GAAP income from operations

$

73,294

 

11.3

%

$

81,594

 

12.9

%

$

239,359

 

12.6

%

$

273,705

 

13.8

%

  GAAP (gains) losses from change in fair market value of equity securities and loan receivable

$

(792,888

)

$

(36,425

)

$

1,680,290

 

$

1,576,542

 

Gains (losses) from change in fair market value of equity securities and loan receivable

 

792,888

 

 

36,425

 

 

(1,680,290

)

 

(1,576,542

)

Non-GAAP (gains) losses from change in fair market value of equity securities and loan receivable

$

-

 

$

-

 

$

-

 

$

-

 

  GAAP other (income) expense, net

$

(18,081

)

$

(20,446

)

$

(70,740

)

$

(87,365

)

Gains (losses) on equity-method investments

 

(1,626

)

 

(697

)

 

(3,349

)

 

(2,543

)

Other non-recurring items (3)

 

-

 

 

2,500

 

 

-

 

 

2,500

 

Non-GAAP other (income) expense, net

$

(19,707

)

$

(18,643

)

$

(74,089

)

$

(87,408

)

  GAAP income (loss) before income taxes

$

861,620

 

$

137,102

 

$

(1,433,583

)

$

(1,278,496

)

Amortization of purchased intangibles

 

5,324

 

 

6,136

 

 

16,077

 

 

18,062

 

Acquisition related (benefits) costs

 

400

 

 

(18,900

)

 

800

 

 

(18,500

)

Restructuring (benefits) costs

 

1,441

 

 

1,532

 

 

7,108

 

 

25,870

 

(Gains) losses from change in fair market value of equity securities and loan receivable

 

(792,888

)

 

(36,425

)

 

1,680,290

 

 

1,576,542

 

(Gains) losses on equity-method investments

 

1,626

 

 

697

 

 

3,349

 

 

2,543

 

Other non-recurring items (2) (3)

 

1,663

 

 

(623

)

 

4,704

 

 

3,294

 

Non-GAAP income before income taxes

$

79,186

 

$

89,519

 

$

278,745

 

$

329,315

 

  GAAP (provision for) benefit from income taxes

$

(208,448

)

$

(30,845

)

$

305,185

 

$

291,464

 

Income tax effect of non-GAAP adjustments (1)

 

185,624

 

 

9,408

 

 

(373,835

)

 

(364,826

)

Non-GAAP provision for income taxes

$

(22,824

)

$

(21,437

)

$

(68,650

)

$

(73,362

)

  GAAP net income (loss)

$

653,172

 

100.5

%

$

106,257

 

16.8

%

$

(1,128,398

)

(59.4

)%

$

(987,032

)

(49.6

)%

Amortization of purchased intangibles

 

5,324

 

 

6,136

 

 

16,077

 

 

18,062

 

Acquisition related (benefits) costs

 

400

 

 

(18,900

)

 

800

 

 

(18,500

)

Restructuring (benefits) costs

 

1,441

 

 

1,532

 

 

7,108

 

 

25,870

 

(Gains) losses from change in fair market value of equity securities and loan receivable

 

(792,888

)

 

(36,425

)

 

1,680,290

 

 

1,576,542

 

(Gains) losses on equity-method investments

 

1,626

 

 

697

 

 

3,349

 

 

2,543

 

Other non-recurring items (2) (3)

 

1,663

 

 

(623

)

 

4,704

 

 

3,294

 

Income tax effect of non-GAAP adjustments (1)

 

185,624

 

 

9,408

 

 

(373,835

)

 

(364,826

)

Non-GAAP net income

$

56,362

 

8.7

%

$

68,082

 

10.8

%

$

210,095

 

11.1

%

$

255,953

 

12.9

%

  GAAP diluted income (loss) per share

$

23.34

 

$

3.64

 

$

(39.89

)

$

(33.63

)

Amortization of purchased intangibles

 

0.19

 

 

0.21

 

 

0.57

 

 

0.61

 

Acquisition related (benefits) costs

 

0.01

 

 

(0.65

)

 

0.03

 

 

(0.63

)

Restructuring (benefits) costs

 

0.05

 

 

0.05

 

 

0.25

 

 

0.88

 

(Gains) losses from change in fair market value of equity securities and loan receivable

 

(28.33

)

 

(1.25

)

 

59.35

 

 

53.47

 

(Gains) losses on equity-method investments

 

0.06

 

 

0.02

 

 

0.12

 

 

0.09

 

Other non-recurring items (2) (3)

 

0.06

 

 

(0.02

)

 

0.17

 

 

0.11

 

Income tax effect of non-GAAP adjustments (1)

 

6.63

 

 

0.33

 

 

(13.21

)

 

(12.38

)

Add back anti-dilutive shares

 

-

 

 

-

 

 

0.03

 

 

0.16

 

Non-GAAP diluted income per share

$

2.01

 

$

2.33

 

$

7.42

 

$

8.68

 

  GAAP diluted weighted average shares used in per share calculation

 

27,985

 

 

29,223

 

 

28,286

 

 

29,349

 

Shares included in non-GAAP net income per share, but excluded from GAAP net loss per share as they would have been anti-dilutive

 

-

 

 

-

 

 

24

 

 

137

 

Non-GAAP diluted weighted average shares used in per share calculation

 

27,985

 

 

29,223

 

 

28,310

 

 

29,486

 

  Reconciliation of net income (loss) to adjusted EBITDA: GAAP net income (loss)

$

653,172

 

100.5

%

$

106,257

 

16.8

%

$

(1,128,398

)

(59.4

)%

$

(987,032

)

(49.6

)%

Interest expense

 

12,174

 

 

12,398

 

 

36,715

 

 

37,078

 

(Provision for) benefit from income taxes

 

208,448

 

 

30,845

 

 

(305,185

)

 

(291,464

)

Depreciation and amortization

 

38,891

 

 

37,278

 

 

112,393

 

 

108,724

 

Foreign currency exchange (gains) losses, net

 

1,641

 

 

(1,680

)

 

(2,012

)

 

(5,280

)

Other income, net

 

(18,081

)

 

(20,446

)

 

(70,740

)

 

(87,365

)

(Gains) losses from change in fair market value of equity securities and loan receivable

 

(792,888

)

 

(36,425

)

 

1,680,290

 

 

1,576,542

 

Dividend from Sartorius AG

 

-

 

 

-

 

 

17,930

 

 

34,766

 

Acquisition related (benefits) costs

 

400

 

 

(18,900

)

 

800

 

 

(18,500

)

Restructuring (benefits) costs

 

1,441

 

 

1,532

 

 

7,108

 

 

25,870

 

Other non-recurring items (2)

 

1,663

 

 

1,877

 

 

4,704

 

 

5,794

 

Adjusted EBITDA

$

106,861

 

16.4

%

$

112,736

 

17.8

%

$

353,605

 

18.6

%

$

399,133

 

20.1

%

(1)

  Excluded items identified in the reconciliation schedule are tax effected by application of a non-GAAP effective tax rate. The non-GAAP tax     provision is adjusted for items, the nature of which and/or tax jurisdiction requires the application of a specific tax rate or treatment.

(2)

  Incremental costs to comply with the European Union's In Vitro Diagnostics Regulation ("IVDR") for previously approved products.

(3)

  Gain from the release of an escrow for the acquisition in 2021 (2023).

2024 Financial Outlook

Forecasted non-GAAP operating margin excludes 85 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as foreign currency fluctuations, future gains or losses associated with certain legal matters, acquisitions and restructuring activities. We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments or future legal charges or benefits), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030533020/en/

Investor Contact: Edward Chung, Investor Relations 510-741-6104 ir@bio-rad.com

Media Contact: Anna Gralinska, Corporate Communications 510-741-6643 cc@bio-rad.com